Cas:71066-01-8 (2S)-2-[(2-methylpropan-2-yl)oxycarbonylamino]heptanoic acid manufacturer & supplier

We serve Chemical Name:(2S)-2-[(2-methylpropan-2-yl)oxycarbonylamino]heptanoic acid CAS:71066-01-8 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

(2S)-2-[(2-methylpropan-2-yl)oxycarbonylamino]heptanoic acid

Chemical Name:(2S)-2-[(2-methylpropan-2-yl)oxycarbonylamino]heptanoic acid
CAS.NO:71066-01-8
Synonyms:(s)-2-tert-butoxycarbonylamino-heptanoic acid;(s)-2-n-boc-amino-heptanoic acid;boc-ahep(2)-oh;boc-(2s)-2-amino-heptanoic acid;n-boc-(s)-2-aminoheptanoic acid
Molecular Formula:C12H23NO4
Molecular Weight:245.31500
HS Code:

Physical and Chemical Properties:
Melting point:N/A
Boiling point:375.9ºC at 760 mmHg
Density:1.048g/cm3
Index of Refraction:1.463
PSA:75.63000
Exact Mass:245.16300
LogP:2.93550

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:


Contact us for information like (s)-2-tert-butoxycarbonylamino-heptanoic acid chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,n-boc-(s)-2-aminoheptanoic acid physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,boc-ahep(2)-oh Use and application,boc-(2s)-2-amino-heptanoic acid technical grade,usp/ep/jp grade.


Related News: Taking Teva as an example, it has 2 large R & D centers and 3 professional R & D centers in 5 countries, which effectively supports the development of Teva’s generic pharmaceutical sector. (2S)-2-[(2-methylpropan-2-yl)oxycarbonylamino]heptanoic acid manufacturer With the speeding up of review and approval, the number of approved innovative drugs in China is about to usher in a year of blowout. (2S)-2-[(2-methylpropan-2-yl)oxycarbonylamino]heptanoic acid supplier This is how an API becomes a medicine. (2S)-2-[(2-methylpropan-2-yl)oxycarbonylamino]heptanoic acid vendor Huahai started with the development of characteristic APIs and pharmaceutical intermediates. At the same time, using the international cooperation platform and the opportunity of the expiry of patent protection of major international original research drugs, Huahai has extended the industrial chain to downstream high value-added preparations, and formed intermediates and materials The complete industrial chain of medicine and preparation integration. (2S)-2-[(2-methylpropan-2-yl)oxycarbonylamino]heptanoic acid factory The two trials studied similar patient populations, Tendler said, but VMP was an old standard of care that’s not really used today in the U.S. Still, Tendler believes the two regimens may both have roles to play based on each patient’s ability to tolerate them. Whichever cocktail physicians choose, the two phase 3 studies have confirmed the benefit of Darzalex in transplant-ineligible patients, he added.